GELS Company Profile and Key Details

GELS has shown mixed momentum, gaining 34.15% over the past week and -13.93% over the past quarter, though year-to-date performance is up 31.25%. Short-term trend indicators are bullishly aligned (SMA20 -7.35%, SMA50 -15.27%, SMA200 -43.31%). The stock’s 14-day RSI is 41.01 (neutral), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -81.8% below its high and over 11.64% above its low. Average 10-day trading volume of 8.10 million shares is significantly above the 3-month average of 4.55 million, indicating heightened recent market interest.

Gelteq Limited Ordinary Shares has 10.71 million shares outstanding. The public float is 5.15 million shares, elevated short interest at 0.48% of float. This equals 33.88 thousand shares. The short ratio is 0.31 days. Institutional investors hold 0.81% of the float. Insiders own 47.53%.

Gelteq Limited Ordinary Shares last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.30. This means the shares are trading below this model’s fair value.

Gelteq Limited Ordinary Shares (NASDAQ:GELS) closed at $0.70 USD, gaining $0.17 (31.58%) from the previous close of $0.53. The stock is currently mid-range between its 52-week high and low $0.39 and $2.02. With a market capitalization of about $6.43 million, Gelteq Limited Ordinary Shares is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.43). Key stats such as the average daily volume over the past year has been around 3.68 million shares, trading with heavier-than-usual volume. Headquartered in Clayton, VIC, Gelteq Limited Ordinary Shares operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Nathan Jacob Givoni, the company employs approximately 18 people and listed since October 29, 2024. Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use.

Gelteq Limited Ordinary Shares trades at a P/E ratio of -2.58, slightly below the S&P 500 average, with a price-to-sales ratio of 47.67 and a price-to-book ratio of 0.68 suggesting the stock is closer to book value. The P/FCF stands at 0.0, also above market averages.

Our AI price prediction model suggests that Gelteq Limited Ordinary Shares stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.86%, with price expected at $0.61 by September 16, 2026, within a range of $0.56 to $0.66 3-Month Outlook: Projected fall of -51.43%, reaching $0.34 by November 30, 2026, with a range of $0.26 to $0.42. 1-Year Outlook: Projected loss of -2.86%, with price at $0.68 by September 02, 2027, within a range of $0.60 to $0.77.

Gelteq Limited Ordinary Shares (NASDAQ:GELS) shares are up 31.25% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Gelteq Limited Ordinary Shares trading at a premium to the broader market with a P/E of -2.58. Our AI forecast model points to short-term weakness (-12.86% over two weeks), a medium-term fall (-51.43% over three months), and a longer-term loss (-2.86% over one year), with expected trading ranges indicating moderate volatility.